Clinical and immunological characteristics of study participants
| Characteristics . | Healthy (n = 28) . | Elderly (n = 6) . | SARC (n = 8) . | ICL (n = 20) . |
|---|---|---|---|---|
| Age, years | 43.5 (24-60) | 91.5 (87-99) | 47.5 (31-76) | 51.5 (24-76) |
| Sex (male:female) | 11:17 | 1:5 | 1:7 | 10:10 |
| CD4+ T-cell count, cells/mm3 | 774 (510-1037) | 478 (330-687)* | 393 (200-723)* | 100 (22-278)*** |
| CD4+ cells, % | 46 (37-55) | 47.5 (34.6-57.2) | 34.5 (20-59) | 23 (3-62)** |
| CD8+ T-cell count, cells/mm3 | 437 (258-615) | 261 (164-375) | 372 (175-393) | 112 (15-691)* |
| CD8+ cells, % | 27 (18-35) | 25 (16-30) | 24 (15-25) | 20 (9-77) |
| CD4:CD8 ratio | 1.7 (0.8-4) | 1.4 (0.8-1.8) | 1.3 (0.6-2.4) | 1 (0.05-2.5)* |
| CD19+ B-cell count, cells/mm3 | 239 (137-341) | 112 (52-278)* | 234 (112-378) | 71 (6-547)*** |
| CD19+ cells, % | 16 (10-21) | 14 (7-20) | 18 (12-26) | 19 (1.5-46) |
| Immunoglobulins (g/L) | ||||
| IgG | 10.9 (6.8-15) | ND | 12.7 (10.9-16.6) | 9.4 (6.2-12.2) |
| IgA | 2.25 (0.75-3.75) | ND | 2.62 (2.58-2.99) | 1.17 (0.4-3.3) |
| IgM | 1.3 (0.40-2.20) | ND | 0.75 (0.66-1.75) | 0.65 (0.37-2.73) |
| Opportunistic infections | ||||
| Human papillomavirus | — | — | — | 6 |
| Varicella zoster virus reactivation | — | 1 | — | 2 |
| Cryptococcus neoformans | — | — | — | 2† |
| Pneumocystis jiroveci | — | — | — | 2 |
| Mycobacterium avium complex | — | — | — | 1† |
| Asymptomatic | — | 5 | — | 8 |
| Dysimmune diseases | ||||
| Autoimmune hemolytic anemia | — | — | — | 1 |
| Systemic lupus erythematosus | — | — | — | 1 |
| Vitiligo | — | — | — | 1 |
| Crohn’s disease | — | — | — | 1 |
| Cytomegalovirus status | ||||
| Serology-positive (IgM− IgG+) | ND | ND | ND | 8 |
| PCR-positive | ND | ND | ND | 0 |
| Characteristics . | Healthy (n = 28) . | Elderly (n = 6) . | SARC (n = 8) . | ICL (n = 20) . |
|---|---|---|---|---|
| Age, years | 43.5 (24-60) | 91.5 (87-99) | 47.5 (31-76) | 51.5 (24-76) |
| Sex (male:female) | 11:17 | 1:5 | 1:7 | 10:10 |
| CD4+ T-cell count, cells/mm3 | 774 (510-1037) | 478 (330-687)* | 393 (200-723)* | 100 (22-278)*** |
| CD4+ cells, % | 46 (37-55) | 47.5 (34.6-57.2) | 34.5 (20-59) | 23 (3-62)** |
| CD8+ T-cell count, cells/mm3 | 437 (258-615) | 261 (164-375) | 372 (175-393) | 112 (15-691)* |
| CD8+ cells, % | 27 (18-35) | 25 (16-30) | 24 (15-25) | 20 (9-77) |
| CD4:CD8 ratio | 1.7 (0.8-4) | 1.4 (0.8-1.8) | 1.3 (0.6-2.4) | 1 (0.05-2.5)* |
| CD19+ B-cell count, cells/mm3 | 239 (137-341) | 112 (52-278)* | 234 (112-378) | 71 (6-547)*** |
| CD19+ cells, % | 16 (10-21) | 14 (7-20) | 18 (12-26) | 19 (1.5-46) |
| Immunoglobulins (g/L) | ||||
| IgG | 10.9 (6.8-15) | ND | 12.7 (10.9-16.6) | 9.4 (6.2-12.2) |
| IgA | 2.25 (0.75-3.75) | ND | 2.62 (2.58-2.99) | 1.17 (0.4-3.3) |
| IgM | 1.3 (0.40-2.20) | ND | 0.75 (0.66-1.75) | 0.65 (0.37-2.73) |
| Opportunistic infections | ||||
| Human papillomavirus | — | — | — | 6 |
| Varicella zoster virus reactivation | — | 1 | — | 2 |
| Cryptococcus neoformans | — | — | — | 2† |
| Pneumocystis jiroveci | — | — | — | 2 |
| Mycobacterium avium complex | — | — | — | 1† |
| Asymptomatic | — | 5 | — | 8 |
| Dysimmune diseases | ||||
| Autoimmune hemolytic anemia | — | — | — | 1 |
| Systemic lupus erythematosus | — | — | — | 1 |
| Vitiligo | — | — | — | 1 |
| Crohn’s disease | — | — | — | 1 |
| Cytomegalovirus status | ||||
| Serology-positive (IgM− IgG+) | ND | ND | ND | 8 |
| PCR-positive | ND | ND | ND | 0 |